Spectrophotometric Determination of Risedronate in Pharmaceutical Formulations via Complex Formation with Cu (II)

M I Walash1, M E-S Metwally, M Eid

  • 1Department of Analytical Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura, Egypt.

Related Concept Videos

Complexometric Titration: Overview00:39

Complexometric Titration: Overview

Complexometric titration involves the formation of a complex by reacting a metal ion with one or more ligands. A visual indicator often detects the end point of a complexometric titration. It is added to the metal solution before the titration, forming a stable metal–indicator complex and imparting color to the solution. As the titration approaches the equivalence point, the excess of the added ligand displaces the indicator from the metal–indicator complex, releasing the free indicator. The...
Complexometric Titration: Ligands00:43

Complexometric Titration: Ligands

Different monodentate and polydentate ligands are used as complexing agents in complexometric titration reactions. The formation of complexes by mono- and bidentate ligands involves two or more intermediate steps, limiting their use as complexing agents. In comparison, polydentate ligands can form complexes with metal ions in a single-step process, facilitating sharper end points. This means polydentate ligands, such as amino carboxylic acid derivatives, are most commonly employed in...
Complexometric EDTA Titration Curves01:20

Complexometric EDTA Titration Curves

EDTA titration curves determine the free metal ion concentration. The titration curve represents the change in concentration of free metal ions (p function) as a function of the volume of EDTA added. This curve consists of three regions: before, at, and after equivalence points. Excess free metal ions are present before the equivalence point. Equal concentrations of metal ions and EDTA are present at the equivalence point. After the equivalence point, excess EDTA exists. This means slight...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Drug Dissolution: Requirements and Profile Comparison01:14

Drug Dissolution: Requirements and Profile Comparison

The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
Precipitation Titration: Endpoint Detection Methods01:19

Precipitation Titration: Endpoint Detection Methods

In argentometric precipitation titrations, endpoints can be detected visually by the Mohr, Volhard, and Fajans methods. In the Mohr method, adding a soluble chromate indicator gives an initial yellow color to the analyte solution. As the titrant is added, the first excess of silver ions forms a red silver chromate precipitate, marking the endpoint. The solution pH should be maintained at about 8 by adding solid CaCO3.
In the Volhard method, a standard excess of AgNO3 is first added to the...